FDA WARNS XCEL ABOUT SALES INFORMATION FOR MIGRAINE DRUGS

Drug Industry Daily
KEYWORDS Advertising / FDA
A A

Xcel Pharmaceuticals’ promotional materials for two migraine products omit risk information, make misleading comparative claims about safety and include unsubstantiated efficacy and indication claims, according to a letter from the FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC).

To View This Article:

Login

Subscribe To Drug Industry Daily